Roche

Roche

A biotechnology company with a focus on developing pharmaceuticals and diagnostics. It was founded in 1896 and is located in Basel, Switzerland.

Roche is a Switzerland-based biotechnology company that develops therapeutics and diagnostics for oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. The company has more than 900,000 employees throughout 100 countries. It states that it is the world's largest biopharmaceutical company and the lead supplier of in vitro diagnostics.

Product

The company has research and development in progress for pharmaceuticals and diagnostics for haemophilia, women's health, inflammatory bowel disease, and neuroscience. The facilities for this research are located in the United States, Austria, Germany, Poland, Switzerland, South Africa and China.Roche conducts clinical trials and once they are successfully completed the pharmaceuticals are produced in an experimental lab to ensure scalability. The company has manufacturing facilities for its therapeutics, including facilities for its biologics.

Roche offers more than 40 pharmaceuticals, including Hemlibra, Micera, and Tamiflu.

Timeline

November 16, 2020

Lead Pharma enters into a collaboration and license agreement with Roche to develop oral small molecules to treat a broad range of immune mediated diseases.

March 2009

Genentech and Roche merge.

1968

Roche enters the diagnostics market.

1896

Roche is founded by Fritz Hoffmann-La Roche in Switzerland.

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients

F. Hoffmann-La Roche Ltd

Web

October 13, 2020

Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting

F. Hoffmann-La Roche Ltd

Web

November 5, 2020

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Alex Keown
November 20, 2020
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Alex Keown
November 20, 2020
BioSpace
The World Health Organization (WHO) recommends against using Gilead Sciences' remdesivir as a treatment for COVID-19.
Alex Keown
November 19, 2020
BioSpace
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The Hanover Insurance Group, Inc.
November 18, 2020
www.prnewswire.com:443
/PRNewswire/ -- The Hanover Insurance Group, Inc. (NYSE: THG) today announced the company's board of directors has accelerated its previously disclosed...
Halozyme Therapeutics, Inc.
November 18, 2020
www.prnewswire.com:443
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in a...
Heather McKenzie
November 18, 2020
BioSpace
Lead Pharma has entered into a collaboration and license agreement with Roche, hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases.
Jazz Pharmaceuticals plc
November 17, 2020
www.prnewswire.com:443
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jennifer Cook and Mark D. Smith, M.D. have been appointed to the Company's Board...
BioSpace
November 16, 2020
BioSpace
R&D collaboration building on Lead Pharma's expertise in the discovery, design and optimization of small molecule treatments
Lead Pharma
November 16, 2020
www.prnewswire.com:443
/PRNewswire/ -- Lead Pharma, a clinical stage pharmaceutical company, designing and developing innovative medicines for the treatment of immune mediated...
Ben Adams
November 13, 2020
FierceBiotech
Roche has handed back the rights to one of its C4 Therapeutics targets as it tweaks a four-year research pact.
November 13, 2020
BioSpace
Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Positive Breast Cancer - read this article along with other careers information, tips and advice on BioSpace
Halozyme Therapeutics, Inc.
November 13, 2020
www.prnewswire.com:443
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for...
BioSpace
November 10, 2020
BioSpace
CEVEC Pharma GmbH (CEVEC) today announced the signing of an option and license agreement with Roche for the use of its newly launched ELEVECTA(R) Technology for large scale manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications.
Research and Markets
November 9, 2020
www.prnewswire.com:443
/PRNewswire/ -- The "Investigation Report on China's Rituximab Market, 2020-2024" report has been added to ResearchAndMarkets.com's offering. The global sales...
Jon Deeks
August 27, 2020
the Guardian
A Covid-19 finger-prick test being carried out in London. Photograph: Yui Mok/PA
Conor Hale
July 17, 2020
FierceBiotech
Roche and its Genentech division have tapped San Francisco-based startup PicnicHealth to help aggregate patient medical records for use in their biomedical research.
Nick Paul
July 14, 2020
FierceBiotech
Roche is paying Blueprint Medicines $775 million upfront for rights to RET inhibitor pralsetinib. The deal sets Roche up to compete with Eli Lilly for patients with RET fusion-positive tumors of organs including the lung and thyroid.
Reuters
July 14, 2020
@bsindia
US company Blueprint, which has been working with Roche since 2016, could also receive up to $927 million in milestone payments, plus royalties on sales outside the United States
Nick Paul
July 13, 2020
FierceBiotech
Roche has posted updated clinical data on a hemophilia A gene therapy it acquired in its $4.3 billion takeover of Spark Therapeutics. The study linked SPK-8011 to improvements in factor VIII expression and bleeding out as far as 3.3 years after administering the therapy, but, with Spark still optimizing the regimen, it will be 2021 before phase 3 dosing begins.
Francesco Guarascio | Reuters
July 9, 2020
@bsindia
The deals cover Roches arthritis drug RoActemra and Mercks multiple sclerosis drug Rebif - both seen as potential COVID-19 therapies
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.